

Clinical trials of death and events prevention for coronary artery disease in all type of patients

TrialResults-center www.trialresultscenter.org

1 aspirin

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|--|
| aspirin vs placebo | | | |
| CDPA , 1976 n=758/771 follow-up: 1.83 y | Aspirin (324 mg) 3x/d versus Placebo | MI survivors | Parallel groups Double blind USA |
| Cardiff I , 1974 n=615/624 follow-up: 2 years | Aspirin (300 mg) 1x/d versus Placebo | MI survivors | Parallel groups Double blind UK |
| Cardiff II , 1979 n=832/850 follow-up: 1 y | Aspirin (300 mg) 3x/d for one year versus Placebo | patients with myocardial infarction | Parallel groups Double blind South Wales |
| Vogel , 1979 n=672/668 follow-up: 1.75 y (mean) | Aspirin (1.5 g daily) on an average period of 22 months versus Placebo | - | Parallel groups Double blind Germany |
| AMIS , 1980 [NCT00000491] n=2267/2257 follow-up: >3 y | Aspirin (500 mg) 2x/d for at least 3 years versus Placebo | men and women who had had a documented myocardial infarction | Parallel groups Double blind USA |
| GAMIS , 1980 n=317/309 follow-up: 2 y | Aspirin (500 mg) 3x/d for 2 years versus Placebo | patients who had survived a myocardial infarction for 30-42 days | Parallel groups Double blind Germany, Austria, |
| PARIS , 1980 n=810/406 follow-up: 41 mo | Aspirin (324 mg) 3x/d versus Placebo | patients who had recovered from myocardial infarction | Parallel groups Double blind USA, UK |
| JAMIS , 1999 n=250/230 follow-up: 1.3 y (mean) | Aspirin (81 mg) 1x/d versus No antiplatelets | patients with AMI within 1 month from the onset of symptoms | Parallel groups Open Japan |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|--|---|
| SAPAT , 1992 n=1009/1026 follow-up: 50 months | aspirin 75 mg daily versus placebo | patients with stable chronic angina pectoris | Parallel groups double blind Sweden |

References

CDPA, 1976:

, Aspirin in coronary heart disease. The Coronary Drug Project Research Group. J Chronic Dis 1976; 29:625-42 [789390]

Cardiff I, 1974:

Elwood P, Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J (Clin Res Ed) 1981; 282:481 [6780093]

Cardiff II, 1979:

Elwood PC, Sweetnam PM, Aspirin and secondary mortality after myocardial infarction. Lancet 1979; 2:1313-5 [92668]

Vogel, 1979:

Folia Haematol 1979; 106:797-803 [0]

AMIS, 1980:

, The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation 1980; 62:V79-84 [7438383]

, A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243:661-9 [6985998]

GAMIS, 1980:

Bredden K, Loew D, Lechner K, Oberla K, Walter E, The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980; 62:V63-72 [6777073]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

JAMIS, 1999:

Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamaguchi T, Motomiya T, Tamura Y, Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 1999; 83:1308-13 [10235086]

SAPAT, 1992:

Juul-Miller S, Edvardsson N, Jahnmatz B, Rosn A, Srensen S, Omblus R Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5 [1360557]

2 clopidogrel

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---------------------------|
| clopidogrel vs aspirin | | | |
| ASCET [NCT00222261] n=498/503 follow-up: | clopidogrel 75 mg once daily for two years versus Aspirin 160 mg once daily for two years | patients with documented coronary heart disease and treated with aspirin | Parallel groups open |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|---|
| CAPRIE , 1996 n=9599/9586 follow-up: 1.91 y | Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years versus Aspirin (325 mg) 1x/d | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | Parallel groups Double blind 16 countries (USA, Canada, Europe, Australia and NZ) |

References

ASCET, :

CAPRIE, 1996:

, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329-39 [8918275]

3 dipyridamol

| Trial | Treatments | Patients | Trials design and methods |
|--|---|-------------------------------|---------------------------------|
| dipyridamol vs control | | | |
| Atlanta (Sbar) , 1967 n=30/30 follow-up: 6 months | dipyridamole 150mg daily versus placebo | patients with angina pectoris | parallel groups double-blind |
| Wirecki , 1967 n=28/28 follow-up: 7 months | dipyridamole 150mg daily versus placebo | patients with angina pectoris | parallel groups double blind |
| Becker , 1967 n=14/13 follow-up: 5 months | dipyridamole 225mg daily versus placebo | - | parallel groups double-blind |
| dipyridamol vs placebo | | | |
| Kinsella , 1962 n=13/13 follow-up: 0.5 months | dipyridamole 37.5 mg and 100mg daily versus placebo | - | parallel groups double-blind |
| Leiberman , 1964 n=19/19 follow-up: >3 months | dipyridamole 100mg daily versus placebo | - | parallel groups double blind |
| Zion , 1961 n=14/14 follow-up: 0.5 months | Dipyridamole 37.5mg versus placebo | patients with angina pectoris | cross-over double-blind |
| Dewar , 1961 n=17/17 follow-up: 0.5 months | Dipyridamole 100mg daily versus placebo | patients with angina pectoris | parallel groups double-blind |
| Neumann , 1964 n=20/16 follow-up: 1.5 months | dipyridamole 150mg daily versus placebo | elderly with precordial pain | parallel groups double-blind |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---|
| Foulds , 1960 n=24/24 follow-up: 1 months | Dipyridamole 200mg daily versus placebo | patients with angina pectoris | parallel groups double-blind |
| Igloe , 1970 n=26/22 follow-up: 2-7 months | Dipyridamole 200mg daily versus placebo | patients with angina pectoris | parallel groups double blind |
| dipyridamol + aspirin vs placebo | | | |
| PARIS , 1980 n=810/406 follow-up: 41 months (mean) | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Placebo | patients who had recovered from myocardial infarction | Parallel groups Double blind USA and UK |
| PARIS-II , 1986 n=1563/1565 follow-up: 23.4 months | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d versus Placebo | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Parallel groups Double blind USA and UK |
| dipyridamol + aspirin vs aspirin | | | |
| PARIS , 1980 n=810/810 follow-up: 41 months | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d versus Aspirin (324 mg) 3x/d | patients who had recovered from myocardial infarction | Parallel groups Double blind USA and GB |

References

Atlanta (Sbar), 1967:

Sbar S, Schlant RC Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7 [5340622]

Wirecki, 1967:

Wirecki M Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-45 [5336520]

Becker, 1967:

Becker MC. Angina pectoris: A double blind study with dipyridamole Journal of the Newark Beth Israel Hospital 1967;18:88-94

Kinsella, 1962:

KINSELLA D, TROUP W, MCGREGOR M Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51 [14456202]

Leiberman, 1964:

LEIBERMAN A, GUGLIELMELLI S PERSANTIN- A DOUBLE BLIND STUDY. Angiology 1964;15:290-2 [14170587]

Zion, 1961:

ZION MM, BRADLOW BA A controlled clinical trial of 'persantin' (R A 8) in angina pectoris. S Afr Med J 1961;35:11-3 [13788617]

Dewar, 1961:

DEWAR HA, HORLER AR A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J 1961;6:149-52 [13722387]

Neumann, 1964:

NEUMANN M, LUISADA AA EFFECT OF RAPID AND SLOW-ACTING "CORONARY" DRUGS ON PRECORDIAL PAIN OF THE AGED. Am J Med Sci 1964;247:156-63 [14124704]

Foulds, 1960:

FOULDS T, MACKINNON J Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J 1960;2:835 [13824151]

Igloe, 1970:

Igloe MC Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc 1970;18:233-41 [4984849]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

PARIS-II, 1986:

Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7:251-69 [2868029]

PARIS, 1980:

, Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980; 62:449-61 [7398002]

4 ticlopidine

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------------|
| ticlopidine vs placebo | | | |
| Berglund , 1985 n=21/17 follow-up: 2m | ticlopidine 500 mg daily versus placebo | middle-aged men with stable incapacitating angina pectoris | parallel groups double blind |

References

Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [3911481]

5 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.